This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01347-06v1 51/3/1112    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Livermore, D. M. Articles by Woodford, N. Search for Related Content PubMed PubMed Citation Articles by Livermore, D. M. Articles by Woodford, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 1112-1114, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01347-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci

David M. Livermore,^* Marina Warner, Shazad Mushtaq, Sarah North, and Neil Woodford

Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom

Received 27 October 2006/ Returned for modification 13 December 2006/ Accepted 24 December 2006

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 µg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 µg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 µg/ml, versus linezolid MICs of 8 to 64 µg/ml; actual values reflected the proportion of gene copies mutated.

Published ahead of print on 8 January 2007.

Present address: Veterinary Laboratories Agency Weybridge, Technology Transfer Unit, New Haw, Addlestone, Surrey KT15 3NB, United Kingdom.